Inavolisib is a new investigational medication that targets specific mutations in breast cancer cells. It belongs to a class of drugs that work by blocking certain proteins involved in cancer cell growth. It is given in combination with fulvestrant to treat advanced breast cancer.

Fulvestrant is a hormone therapy medication that blocks the effects of estrogen on cancer cells. It is commonly used to treat hormone receptor-positive breast cancer in postmenopausal women whose disease has progressed after other hormone treatments.

Alpelisib is a targeted therapy medication that blocks specific proteins involved in cancer cell growth. Like inavolisib, it is used in combination with fulvestrant to treat certain types of advanced breast cancer that have specific genetic mutations.

CDK4/6 inhibitors are a class of medications that work by blocking specific proteins involved in cell division. These medications are typically used in combination with hormone therapy to treat hormone receptor-positive breast cancer.

Metastatic Breast Cancer – A form of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, most commonly to the bones, liver, lungs, or brain. The cancer cells break away from the original tumor and travel through the bloodstream or lymphatic system to form new tumors in other organs. The disease develops when breast cancer cells gain the ability to detach from the primary tumor and establish growth in distant locations. The progression of metastatic breast cancer can vary significantly among individuals. The condition is characterized by the presence of breast cancer cells in organs distant from the breast tissue.